Hjem
Jone Troviks bilde

Jone Trovik

Professor
  • E-postJone.Trovik@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Lærebok
  • Vis forfatter(e) (2020). Obstetrics and Gynecology. NFOG textbook for medical students. Nordic Federation of Societies of Obstetrics and Gynecology .
Vitenskapelig artikkel
  • Vis forfatter(e) (2021). Salvage radiation for pelvic relapse after surgically treated endometrial cancer. Cancers. 1-11.
  • Vis forfatter(e) (2021). Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. American Journal of Obstetrics and Gynecology. 1-20.
  • Vis forfatter(e) (2021). Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecologic Oncology. 787-794.
  • Vis forfatter(e) (2021). Handheld transabdominal ultrasound, after limited training, may confirm first trimester viable intrauterine pregnancy: a prospective cohort study. Scandinavian Journal of Primary Health Care. 123-130.
  • Vis forfatter(e) (2021). Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 25-31.
  • Vis forfatter(e) (2021). An mri-based radiomic prognostic index predicts poor outcome and specific genetic alterations in endometrial cancer. Journal of Clinical Medicine. 1-11.
  • Vis forfatter(e) (2021). A patient-clinician James Lind Alliance partnership to identify research priorities for hyperemesis gravidarum. BMJ Open. 1-9.
  • Vis forfatter(e) (2021). A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer. 1690-1698.
  • Vis forfatter(e) (2020). Whole-volume tumor MRI radiomics for prognostic modeling in endometrial cancer. Journal of Magnetic Resonance Imaging. 1-10.
  • Vis forfatter(e) (2020). Tumour texture features from preoperative CT predict high-risk disease in endometrial cancer. Clinical Radiology. 1-8.
  • Vis forfatter(e) (2020). Prognostic value of the diversity of nuclear chromatin compartments in gynaecological carcinomas. Cancers. 1-16.
  • Vis forfatter(e) (2020). Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine.
  • Vis forfatter(e) (2020). Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. European Radiology. 2443-2453.
  • Vis forfatter(e) (2020). Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Vis forfatter(e) (2020). High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Vis forfatter(e) (2020). Gynekologiske fistler etter kirurgi og strålebehandling. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2020). Early maternal weight gain as a risk factor for SGA in pregnancies with hyperemesis gravidarum: A 15-year hospital cohort study. BMC Pregnancy and Childbirth. 1-10.
  • Vis forfatter(e) (2020). Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Vis forfatter(e) (2019). Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer. 1037-1044.
  • Vis forfatter(e) (2019). Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLOS ONE. 1-13.
  • Vis forfatter(e) (2019). PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Vis forfatter(e) (2019). Novel PCDH10-Wnt-MALAT1 regulatory axis in endometrioid endometrial adenocarcinoma. Hong Kong Medical Journal. 17-22.
  • Vis forfatter(e) (2019). Incidence of gynecological fistula and its surgical treatment: A national registry-based study. Acta Obstetricia et Gynecologica Scandinavica. 1-7.
  • Vis forfatter(e) (2019). Endometrial ablation; Less is more? Historical cohort study comparing long-term outcomes from two time periods and two treatment modalities for 854 women. PLOS ONE. 1-16.
  • Vis forfatter(e) (2019). Coping with a disruptive life caused by obstetric fistula: Perspectives from Malawian women. International Journal of Environmental Research and Public Health (IJERPH). 1-14.
  • Vis forfatter(e) (2019). Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • Vis forfatter(e) (2019). Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Vis forfatter(e) (2019). Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology. 90-98.
  • Vis forfatter(e) (2018). Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging. 1637-1647.
  • Vis forfatter(e) (2018). Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica. 1010-1017.
  • Vis forfatter(e) (2018). L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition. Virchows Archiv. 591-598.
  • Vis forfatter(e) (2018). Identification of nine new susceptibility loci for endometrial cancer. Nature Communications. 1-12.
  • Vis forfatter(e) (2018). Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Vis forfatter(e) (2018). High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Vis forfatter(e) (2018). Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Medicine. 1978-1987.
  • Vis forfatter(e) (2018). Chromatin organisation and cancer prognosis: a pan-cancer study. The Lancet Oncology. 356-369.
  • Vis forfatter(e) (2018). Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology. 46-52.
  • Vis forfatter(e) (2018). Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers. Journal of the National Cancer Institute. 1400-1408.
  • Vis forfatter(e) (2018). Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: An International Journal of Obstetrics and Gynaecology. 1695-1703.
  • Vis forfatter(e) (2018). Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology-based endometrial carcinoma recurrence prediction models: An ENITEC Collaboration study. International Journal of Gynecological Cancer. 514-523.
  • Vis forfatter(e) (2017). Type of vascular invasion in association with progress of endometrial cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1084-1091.
  • Vis forfatter(e) (2017). Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. OncoTarget. 109018-109026.
  • Vis forfatter(e) (2017). Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • Vis forfatter(e) (2017). Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Vis forfatter(e) (2017). Potential targets' analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas - An ENITEC group initiative. Clinical Cancer Research. 1274-1285.
  • Vis forfatter(e) (2017). PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Vis forfatter(e) (2017). Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer Letters. 23-34.
  • Vis forfatter(e) (2017). Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. PLOS ONE. 1-12.
  • Vis forfatter(e) (2017). In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • Vis forfatter(e) (2017). High visceral fat percentage is associated with poor outcome in endometrial cancer. OncoTarget. 105184-105195.
  • Vis forfatter(e) (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Vis forfatter(e) (2017). Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • Vis forfatter(e) (2017). Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer. 840-847.
  • Vis forfatter(e) (2017). Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • Vis forfatter(e) (2017). Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology. 197-203.
  • Vis forfatter(e) (2016). Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Vis forfatter(e) (2016). The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Vis forfatter(e) (2016). Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports.
  • Vis forfatter(e) (2016). L1CAM expression in endometrial carcinomas: An ENITEC collaboration study. British Journal of Cancer. 716-724.
  • Vis forfatter(e) (2016). Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clinical Cancer Research. 513-523.
  • Vis forfatter(e) (2016). Incidence of obstetric fistula in Norway: A population-based prospective cohort study. Acta Obstetricia et Gynecologica Scandinavica. 405-410.
  • Vis forfatter(e) (2016). Hyperemesis Gravidarum is associated with substantial economic burden in addition to severe physical and psychological suffering. Israel Journal of Health Policy Research.
  • Vis forfatter(e) (2016). Genetic risk score mendelian randomization shows that obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 1503-1510.
  • Vis forfatter(e) (2016). Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics. 667-674.
  • Vis forfatter(e) (2016). Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. Cancer Epidemiology, Biomarkers and Prevention. 61-67.
  • Vis forfatter(e) (2016). CYP19A1 fine-mapping and Mendelian randomization: Estradiol is causal for endometrial cancer. Endocrine-Related Cancer. 77-91.
  • Vis forfatter(e) (2016). Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Vis forfatter(e) (2016). Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Vis forfatter(e) (2015). Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas. Clinical Radiology. 487-494.
  • Vis forfatter(e) (2015). Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. OncoTarget. 39676-39691.
  • Vis forfatter(e) (2015). Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. International Journal of Gynecological Cancer. 459-466.
  • Vis forfatter(e) (2015). Norwegian PUQE (pregnancy-unique quantification of emesis and nausea) identifies patients with hyperemesis gravidarum and poor nutritional intake: A prospective cohort validation study. PLOS ONE. 15 sider.
  • Vis forfatter(e) (2015). Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Vis forfatter(e) (2015). Metabolic tumor volume on 18F-FDG PET/CT improves preoperative identification of high-risk endometrial carcinoma patients. Journal of Nuclear Medicine. 1191-1198.
  • Vis forfatter(e) (2015). Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports.
  • Vis forfatter(e) (2015). Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. OncoTarget. 10634-10645.
  • Vis forfatter(e) (2015). Hyperemesis gravidarum, nutritional treatment by nasogastric tube feeding: A 10-year retrospective cohort study. Acta Obstetricia et Gynecologica Scandinavica. 359-367.
  • Vis forfatter(e) (2015). Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics. 1478-1492.
  • Vis forfatter(e) (2015). DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer. British Journal of Cancer. 1656-1664.
  • Vis forfatter(e) (2015). Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer. 851-861.
  • Vis forfatter(e) (2015). Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics. 231-245.
  • Vis forfatter(e) (2015). ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Vis forfatter(e) (2014). Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Vis forfatter(e) (2014). Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Vis forfatter(e) (2014). Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer.
  • Vis forfatter(e) (2014). Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. 603-610.
  • Vis forfatter(e) (2014). Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • Vis forfatter(e) (2014). Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer. 107-114.
  • Vis forfatter(e) (2014). Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Vis forfatter(e) (2014). High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Vis forfatter(e) (2014). Growth differentiation factor-15 as biomarker in uterine sarcomas. International Journal of Gynecological Cancer. 252-259.
  • Vis forfatter(e) (2014). Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Vis forfatter(e) (2014). Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics. 231-245.
  • Vis forfatter(e) (2014). A novel Wnt regulatory axis in endometrioid endometrial cancer. Cancer Research. 5103-5117.
  • Vis forfatter(e) (2013). Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas. Gynecologic Oncology. 410-415.
  • Vis forfatter(e) (2013). Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • Vis forfatter(e) (2013). Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • Vis forfatter(e) (2013). Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 sider.
  • Vis forfatter(e) (2013). Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
  • Vis forfatter(e) (2013). High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • Vis forfatter(e) (2013). Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
  • Vis forfatter(e) (2013). ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • Vis forfatter(e) (2013). A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis. European Journal of Cancer. 625-632.
  • Vis forfatter(e) (2012). Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists. European Radiology. 1601-1611.
  • Vis forfatter(e) (2012). SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. European Journal of Cancer. 1988-1996.
  • Vis forfatter(e) (2012). Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecologic Oncology. 103-108.
  • Vis forfatter(e) (2012). Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas. Gynecologic Oncology. 413-418.
  • Vis forfatter(e) (2012). MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. PLOS ONE. 6 sider.
  • Vis forfatter(e) (2012). Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • Vis forfatter(e) (2012). KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • Vis forfatter(e) (2012). Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. Gynecologic Oncology. 381-387.
  • Vis forfatter(e) (2012). High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Vis forfatter(e) (2012). Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
  • Vis forfatter(e) (2011). The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium a collaborative study. International Journal of Gynecological Cancer. 332-336.
  • Vis forfatter(e) (2011). Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. Clinical Cancer Research. 3368-3377.
  • Vis forfatter(e) (2011). High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • Vis forfatter(e) (2011). Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature Genetics. 451-454.
  • Vis forfatter(e) (2011). Evolution in endometrial cancer evidence from an immunohistochemical study. International Journal of Gynecological Cancer. 316-322.
  • Vis forfatter(e) (2011). Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clinical Cancer Research. 4825-4833.
  • Vis forfatter(e) (2009). Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecologic Oncology. 491-495.
  • Vis forfatter(e) (2009). Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • Vis forfatter(e) (2009). Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
  • Vis forfatter(e) (2008). Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 8713-8717.
  • Vis forfatter(e) (2007). Gynekologiske fistler til urinveier og tarm. Tidsskrift for Den norske legeforening. 417-420.
Vitenskapelig foredrag
  • Vis forfatter(e) (2019). European antiemetic regulations (restricting metoclopramide use) increases admission rates due to hyperemesis gravidarum.
  • Vis forfatter(e) (2015). Preoperative tumor texture at MRI predicts deep myometrial invasion and non-endometrioid subtype in endometrial carcinomas.
Leserinnlegg
  • Vis forfatter(e) (2015). Kvantifisering av svangerskapskvalme :. Tidsskrift for Den norske legeforening. 1018-1019.
  • Vis forfatter(e) (2014). Ikke "bare" svangerskapskvalme. Tidsskrift for Den norske legeforening. 430-430.
  • Vis forfatter(e) (2012). Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
  • Vis forfatter(e) (2010). Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 641-646.
Doktorgradsavhandling
  • Vis forfatter(e) (2012). Endometrial cancer; can biomarkers aid in the prediction of aggressive disease? A study with focus on preoperative tumour markers.
Intervju
  • Vis forfatter(e) (2014). - Alle kvinner bør ta denne vaksinen.
Sammendrag/abstract
  • Vis forfatter(e) (2013). FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 sider.
  • Vis forfatter(e) (2012). Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • Vis forfatter(e) (2012). Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. 18-18.
  • Vis forfatter(e) (2012). A discordant histological risk classification in preoperative biopsy and hysterectomy specimens in endometrial cancer is reflected in metastatic risk and prognosis. Acta Obstetricia et Gynecologica Scandinavica. 145-146.
Poster
  • Vis forfatter(e) (2015). Nasogastric feeding in hyperemesis gravidarum; tube positioning by ward nurse, a pilot study.
  • Vis forfatter(e) (2014). Metabolic tumor volume on FDG-PET/CT predicts deep myometrial invasion, lymph node metastases and survival in patients with endometrial carcinoma .
  • Vis forfatter(e) (2009). Stathmin is superior to AKT and Phospho-AKT staining to detect PI3Kinase activation and aggressive endometrial cancer.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2019). Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nature Reviews Disease Primers. 1-17.
  • Vis forfatter(e) (2012). Markers for individualised therapy in endometrial carcinoma. The Lancet Oncology. E353-E361.

Se fullstendig oversikt over publikasjoner i CRIStin.